Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSGJ-706 + carboplatin + paclitaxel
- Development stage
- Phase 2
- Lead developer
- 3SBio
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SSGJ-706 + carboplatin + paclitaxel is a *combination therapeutic regimen* comprising SSGJ-706, a recombinant bispecific antibody developed by Sansheng Guojian to promote T cell activation and enhance anti-tumor immune response, and two established chemotherapeutic agents, **carboplatin (a platinum-based DNA crosslinker)** and **paclitaxel (a microtubule inhibitor)**. SSGJ-706 simultaneously targets two immune-related molecules associated with tumor immunosuppression, aiming to potentiate immune-driven tumor cell killing. Carboplatin and paclitaxel act primarily as cytotoxic agents, with demonstrated efficacy and use in solid tumors, particularly non-small cell lung cancer (NSCLC), ovarian cancer, and other advanced malignancies. This three-drug regimen is being evaluated in clinical studies for **advanced non-small cell lung cancer (NSCLC)**, with trial endpoints focusing on efficacy, safety, and immunogenicity, notably in patients with locally advanced or metastatic disease[1][3][5].
- Other names
- SSGJ-706 + carboplatin + paclitaxel
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SSGJ-706 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSGJ-706 + carboplatin + paclitaxel.